Allergy Treatment Market Outlook (2022-2033)

Increasing Prevalence of Allergic Conditions

The rise in allergic conditions worldwide is caused by environmental, lifestyle, and diagnostic trends. Urban pollution exposure, the effects of climate change, such as longer pollen seasons, and indoor living conditions have all contributed to people becoming more sensitive, and therefore, there are more cases of allergic rhinitis, asthma, skin allergies, and food allergies. Studies show that from 10% to 30% of the world's population could be affected by allergies each year, with respiratory and food allergies being the most common ones in both developed and underdeveloped areas.

Increased public awareness and better screening procedures have also played a part in raising the number of diagnoses, which in turn has created a demand for new and effective treatments. Pharmaceutical research and development—like more efficient biologics and sublingual immunotherapy options—are not only making it easier for doctors to treat patients but also encouraging them to start treating patients earlier rather than just managing symptoms. For instance, the trend of using sublingual immunotherapy is still on the rise as patients prefer this method over traditional antihistamines and want to get long-term relief, which in turn supports the growth of the market that is associated with the increasing incidence of allergies and changing treatment expectations.

Innovation and New Treatment Developments

Pharma companies are not only targeting the traditional symptom suppression but also actively developing next-generation therapies that will meet the unmet needs of the market, including novel biologics, precision immunotherapies, and better delivery methods. For example, the strategic alliances have recently unveiled the next-generation sublingual immunotherapy (SLIT) tablets for the treatment of dust mite and pollen allergies in the key markets, which shows a change towards more patient-friendly, at-home treatments that will lead to better compliance and consequently, longer-term results. At the same time, the clinical trials for the biologic agents that target allergies through dual pathways (e.g., IL-13/TSLP) are being conducted, and they are expected to have a wider range of effect in patients with co-existing conditions such as rhinitis and asthma. Digital diagnostics and collaborations—such as the ones involving digital biomarker profiling—are making it possible to provide more personalized treatment plans and thus creating more opportunities for individualized care. All these innovations now allow the market to take full advantage of the increasing demand for precision medicine while being able to differentiate their offerings in the highly competitive global marketplaces.

The " Allergy Treatment Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• Allergy treatment market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Allergy treatment market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Allergy treatment market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the allergy treatment market
• Detailed company profiles, including SWOT analysis

The geographical scope of the allergy treatment market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. The allergy treatment market in Asia Pacific is expected to grow significantly during the forecast period.

The Asia-Pacific allergy treatment market is segmented into China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, and the Rest of Asia. The Asia-Pacific allergy treatment market is experiencing robust growth, due to growing urban development and industrialization at a rapid pace across countries such as China, India, and Southeast Asia have played a major role in increasing the exposure of people to air pollution and allergens, along with changing their lifestyles, thus, resulting in more cases of respiratory, skin, and food allergies. Global warming has also made the situation worse by lengthening pollen seasons in certain areas of Australia, Japan, and China; thus, the cases of allergic rhinitis and asthma have increased. The patient pool is further enlarged by a large and rising population, especially the kids and the elderly, who are more prone to getting allergies.

Moreover, the healthcare infrastructure is getting better, and thus the healthcare expenditure is going up, which is making access to better diagnosis and treatment easier and is mainly benefiting the urban population. Governments are putting money into public health awareness programs and insurance coverage expansion, which would make it easier for patients to seek medical care instead of just managing the symptoms themselves. The region is also seeing a rise in the number of over-the-counter anti-allergy medications available and the gradual acceptance of advanced therapies like immunotherapy and biologics in developed markets such as Japan and South Korea. Besides, low-cost manufacturing and wide pharmaceutical distribution networks are the reasons the Asia-Pacific is a region where both domestic and international players would want to be, since it would lead to an overall market acceleration.        

• The report includes qualitative and quantitative data in the Allergy Treatment Market across allergy type, treatment type, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the allergy treatment market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the allergy treatment market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the allergy treatment market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 10 cover Allergy Treatment Market segments by allergy type, treatment type, distribution channel, and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. They cover the market revenue forecast and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the allergy treatment market. Companies have been profiled on the basis of their key facts, business descriptions, products and services, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The allergy treatment market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the allergy treatment market are:

• In February 2024, Novartis made a statement that the US Food and Drug Administration (FDA) had given approval to Xolair (omalizumab) for the treatment of allergic reactions, including anaphylaxis that may occur as a result of unintentional exposure to one or more foods in adult and pediatric patients aged one year and older with IgE-mediated food allergy. Xolair has become the first and only FDA-approved medication that can diminish allergic reactions in those having more than one food allergy.
• In April 2025, Dupixent (dupilumab) was officially approved by the US Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents 12 years and older who are still symptomatic despite receiving histamine-1 (H1) antihistamine treatment. Dupixent has already been authorized for CSU in countries like Japan, the United Arab Emirates, and Brazil.